Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Coho
4 hours ago
- #Trastuzumab deruxtecan
- #HER2-mutant NSCLC
- #Real-world evidence
- Trastuzumab deruxtecan (T-DXd) shows strong efficacy in HER2-mutant non-small cell lung cancer (NSCLC) in real-world settings.
- Objective response rate (ORR) was 54.8%, with a disease control rate of 88.7% among 168 patients.
- Median progression-free survival (PFS) was 7.2 months, and overall survival (OS) was 18.3 months.
- Treatment-naïve patients achieved an ORR of 72.2% and median OS of 22.1 months.
- Patients with measurable brain metastases had an intracranial ORR of 74.1%, including 25.9% complete responses.
- Grade ≥3 treatment-related adverse events occurred in 32% of patients, with interstitial lung disease (ILD)/pneumonitis in 14% (including four fatal cases).
- The study supports integrating HER2-targeted therapies into NSCLC treatment algorithms.